|  |
| --- |
| **Study Title:** |
| **Investigator:** | **IRB#:** |

**Instructions:** Complete the Sponsor/Sponsor-Investigator IND Regulatory Documentation Checklist periodically to document that regulatory documentation has been reviewed and is current. For trials with non-Emory sites, also complete monitoring checklist multi-site trials. See [IND/IDE Regulatory Documentation Checklist Item Descriptions](http://www.or.emory.edu/research-compliance/oric/documents1/SI_INDIDE_RDCID.docx) for additional information.

|  |  |  |
| --- | --- | --- |
|  **Document** | **Yes, No or N/A** | **Comments:** Note if an item is maintained in a location other than the regulatory binder and confirm documentation of the location in the regulatory binder |
| **FDA submissions with accompanying 1571**Original application**;** FDA correspondence; Amendments; IND Safety Reports (MedWatch); Annual reports |  | IND Anniversary Date\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_Current IND Annual Report ­­­\_\_\_\_\_\_\_\_\_\_\_\_Date submitted to FDA\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_Date submitted to IRB\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| **Investigator Brochure(s)/Package Insert(s) with Signature Pages, if applicable** |  | Current version/date­­­­­\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_Date submitted to IRB \_\_\_\_\_\_\_\_\_\_\_\_\_ |
| **Protocol/ Protocol Amendment(s) with Signature Page(s), if applicable** |  | Current version/date­­­­­\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_Date approved by IRB \_\_\_\_\_\_\_\_\_\_\_\_\_Current study approval period: \_\_\_\_\_\_\_\_\_\_\_ |
| **ICF, HIPAA Authorization Form and, if applicable, Revocation letter**  |  | Current ICF version/date­­­­­\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_Date approved by IRB \_\_\_\_\_\_\_\_\_\_\_\_\_Current Authorization version/date­­­­\_\_\_\_\_\_\_Date approved by IRB \_\_\_\_\_\_\_\_\_\_\_\_\_ |
| **Institutional Review Board reviews**Documentation of IRB Approval: protocol and amendments, continuing review, ICFs, trial information for subjects, advertisement, and other  |  | Current study approval period: \_\_\_\_\_\_\_\_\_\_\_ |
| **Form FDA 1572** signed by Site PI with current listing of all sub-investigators & facilities |  |  |
| **CV, Licenses** and/or other relevant documents evidencing qualifications of investigators and sub investigatorslisted on Form 1572 |  |  |
| **FDA** [**Financial Disclosure Certification Forms**](http://www.or.emory.edu/research-compliance/oric/documents1/fda_financial_disclosure_certification.docx) (FDF) completed by each investigator listed on Form 1572 |  |  |
| [**Delegation of Authority (DOA) Log**:](http://www.ctac.emory.edu/clinical_trial_resources/delegation_of_authority_log.doc) may include Site Signature log(s) |  |  |
| **Records of Study Specific training** including updates for each individual listed on Delegation Log |  |  |
| **Reportable Events: SAEs, UPs or non-compliance** includingSafety Reports, internal & external with documentation of review by the [**S-I Adverse Event Assessment Form**](http://www.or.emory.edu/research-compliance/oric/documents1/SI_DrugAdverseEventAssessmentForm.docx) |  | Required Reports to IRB, date:\_\_\_\_\_\_ |
| **Data and Safety Monitoring Committee Reports** |  | Required Reports to IRB, date:\_\_\_\_\_\_ |
| **Site Monitoring Log & Reports** |  | Site monitoring completed, date:\_\_\_\_\_\_\_\_Required Reports to CTAC, date:\_\_\_\_\_\_ |
| **clinicaltrials.gov information updated within past 6 months** |  | Updated:**\_\_\_\_\_\_\_\_\_\_\_\_\_** |
| **Investigational Drug** documentationCopy of Label(s) Attached to IP; Shipping Records for IP (note if managed by IDS) |  |  |
| **Screening and Enrollment Log(s)** |  |  |
| **Laboratory**Certifications/Accreditations; Normal Lab Values |  |  |
| **Ancillary Committee Approval(s), if applicable** |  |  |
| **Miscellaneous** |  |  |
| Signature of person completing this form |  | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Date: |